9/11/2020 8:39:38 AM
BioMarin To Present Data From Phase 3, Placebo-controlled, Multicenter Trial For Vosoritide
9/8/2020 9:06:36 AM
BioMarin : Vosoritide Phase 3 Data Shows Significant Increase In AGV Over 52 Weeks In Children With Achondroplasia
8/20/2020 8:34:17 AM
BioMarin Submits NDA For Vosoritide To Treat Children With Achondroplasia
8/19/2020 8:03:16 AM
BioMarin Receives CRL From FDA For Valoctocogene Roxaparvovec Gene Therapy For Severe Hemophilia A
8/13/2020 8:36:39 AM
BioMarin Pharma: EMA Validates Marketing Authorization Application For Vosoritide To Treat Children With Achondroplasia
8/4/2020 4:13:10 PM
BioMarin Q2 Loss/share $0.16 Vs. Loss $0.21 Year Ago
6/29/2020 6:07:10 PM
BioMarin Promotes Brian Mueller To EVP, CFO
6/18/2020 9:43:35 AM
Wedbush Reiterates Biomarin Pharmaceutical Inc. (BMRN) At Outperform With $145 Price Target
6/17/2020 9:22:55 AM
BioMarin Announces Addl. Data From Four-year Update Of An Open-label Phase 1/2 Study Of Valoctocogene Roxaparvovec